LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology (NCT03244020) | Clinical Trial Compass
By InvitationPhase 4
LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
United States2,868 participantsStarted 2018-02-16
Plain-language summary
Aspirin and low molecular weight heparin (LMWH) are both commonly employed pharmacologic methods of venous thromboembolism (VTE) prophylaxis after orthopaedic surgery. Data comparing these two methods of VTE prophylaxis in patients undergoing pelvic/lower extremity orthopaedic surgery for malignancy are lacking, however, as compared to the data and guidelines present for VTE chemoprophylaxis after joint arthroplasty and hip fracture surgery. In this clinical trial, our specific aim is to compare the post operative incidence of VTE between patients receiving aspirin and LMWH after pelvic/lower extremity orthopaedic oncology procedures.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥18 years
✓. Prior or planned surgery on the pelvis or lower extremity
✓. Fulfills one of the following:
✓. Anticoagulation therapy was received or is planned.
Exclusion criteria
✕. Documented prior history of VTE.
✕. Preoperative use of therapeutic or prophylactic chemical anticoagulation at the time of surgery.
✕. Documented allergy/adverse reaction to either of the two study drugs.
✕. Presence of inferior vena cava (IVC) filter.
✕. Known, diagnosed hypercoagulable state (other than malignancy).
✕. Inability to receive chemical anticoagulation.
✕. Preoperative use of full-strength aspirin 325 mg daily; patients already taking aspirin 81 mg daily will not be excluded.
What they're measuring
1
Venous thromboembolism
Timeframe: Up to 3 or 6 months post operatively for bone/soft tissue sarcomas and metastatic osseous disease, respectively